Urologists at Vanderbilt Health are enrolling men with stress urinary incontinence (SUI) in a clinical trial named SOPHIA2 to assess the safety and efficacy of the UroActive implant, following an investigational device exemption clearance from the U.S. Food and Drug Administration and the French National Agency for the Safety of Medicines and Health Products.